Orchid Pharma Limited has informed the Exchange about General Updates

Nclt Scheme FiledStrategic Transactions View source PDF Explain this filing

ORCHPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.0%Reaction day

₹735.00

prior close

₹735.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.3%-1.3% vs market

Pharmaceuticals peers, median of 150sector+0.8%-0.8% vs sector

On the reaction day the stock moved 1.3 pts less than Nifty Microcap 250 and 0.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.1

10m

+0.4

15m

+0.0

30m

-0.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.0+1.3-1.3+0.8-0.8

Next day

-0.1+2.1-2.3+0.7-0.8

+0.8+3.1-2.3+1.4-0.6

-1.7+2.5-4.2+1.0-2.7

-3.3+2.5-5.7+1.1-4.4

-3.7+2.9-6.6+1.7-5.5

-3.0+3.5-6.5+1.9-4.8

15d

+4.2+4.7-0.5+2.1+2.1

-2.2+0.9-3.1-0.5-1.7

+5.3+4.5+0.8+0.3+5.1

+16.1+0.3+15.8-3.9+20.0

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 150Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Orchid Pharma has informed the stock exchanges that, following an NCLT Chennai order dated August 5, 2025, the company has completed the required public notice publications for the proposed amalgamation of Dhanuka Laboratories (Amalgamating Company) into Orchid Pharma (Amalgamated Company). The notices were published in the Indian Express (English, all-India edition) and Dina Thanthi (Tamil Nadu edition). This is a routine procedural step under the SEBI Listing Regulations, continuing from the earlier intimation of July 10, 2025 when the Joint Second Motion Petition was filed with the NCLT. No swap ratio, valuation, or financial terms have been disclosed in this filing.

Likely market impact

This is a procedural update in an ongoing amalgamation process and does not change the deal's economics. Shareholders should await further updates on the swap ratio, NCLT/NCLAT approvals, and the scheme's effective date for the real impact on shareholding and stock price.